BillHR 2821 · 119

FDA Modernization Act 3.0

Introduced

Apr 10, 2025

Cosponsors

Traction

Last Action

Jun 18, 2026

Bill Summary

Reforms the US Food and Drug Administration (FDA) by updating its regulations and procedures. Updates the FDA's approval process for new medicines and treatments.

Bill Journey

Apr 10, 2025
Jun 18, 2026You Are Here
The full chamber debates the bill, may amend it, and votes on whether to pass it.
TBD
If passed by the first chamber, the other chamber considers, may amend, and votes on the bill.
TBD
If passed by both chambers, the bill goes to the President to sign into law or veto.

Why It Matters

This bill affects the pharmaceutical industry, medical researchers, and patients by potentially changing how new medicines and treatments are approved and made available. It may also impact FDA staff and the overall public health by altering the agency's regulatory framework.

Impact Areas

Sample

Addresses Supply

Targets an underlying shortage driving costs.

Supports Families

Aimed at easing pressure on working households.

Long-term Impact

Effects compound across multiple budget cycles.

Expands Access

Lowers barriers for first-time participants.

Support & Opposition

Sponsor & cosponsor support by party

Democratic20
Republican21

Cross-party cosponsors20 · 50%

Documents

Full Bill Text
H.R. 2821 · congress.gov

Full text opens on congress.gov, the official source.

Cosponsors (41)

Show all 36 more

1 more not shown here — see the full list on congress.gov.

Bill Details

Bill TypeHouse Bill · Federal

Primary TopicHealth

CommitteeHouse Committee (sample)Sample

IntroducedApr 10, 2025

Last UpdatedJun 18, 2026

Latest ActionPlaced on the Union Calendar, Calendar No. 614.

Subjects

Health

Summary and impact analysis written by Judy (KnowGov's enrichment AI). Bill metadata, status, sponsor, and any floor votes from Prism. Sections marked “Sample” are placeholders not yet connected to live data.